Breast Cancer Protocols

  • CALGB 40101: Cyclophosphamide and Doxorubicin (AC) (4 vs 6 Cycles) vs Paclitaxel (4 vs 6 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A 2 x 2 Factorial Phase III Randomized Study
  • PACCT-1: Program for the Assessment of Clinical Cancer Tests: Trial Assigning Individualized Options for Treatment. (TAILOR-X).
  • SOFT Trial: Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Pre-menopausal Women with Endocrine Responsive Breast Cancer.
  • ACOSOG Z1031: Randomized Phase III Trial Comparing 16-18 Weeks of Neoadjuvant Exemestane, Letrozole or Anastrozole in Post-menopausal Women with Stage II/III Estrogen Positive Breast Cancer.
  • RWH# 300-04: Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
  • RWH# 355-45 (Br 211-A): Q3 Week Carboplatin with Weekly Abraxane™ and Avastin™ and Subsequent Dose-Dense AC with Avastin™ Neoadjuvant Therapy in Resectable and Unresectable (Stage IIA-IIIB) HER2-Negative Breast Cancer: A BrUOG Phase II Study
  • RWH# 356-45 (Br 211-B): Q3 Week Carboplatin with Weekly Abraxane™ and Trastuzumab as Neoadjuvant Therapy in Resectable and Unresectable (Stage IIA-IIIB) HER2-Positive Breast Cancer: A BrUOG Phase II Study

Contact information

  • Robin Davies, B.A., B.S.N., R.N.
    RWMC Protocol Office Manager
    Phone: (401) 456-2268 - Fax: (401) 456-2658 - rdavies@rwmc.org
  • Frances D’Allesandro, C.R.A.
    Clinical Research Coordinator, RWMC Protocol Office
    Phone: (401) 456-2698 - Fax: (401) 456-2658 - fdallesando@rwmc.org
  • Jessica Donaghy A.S.
    Administrative Associate, RWMC Protocol Office
    Phone: (401) 456-5393 - Fax: (401) 456-2658 - jdonaghy@rwmc.org